Ghazaleh Nameni, Shima Jazayeri, Somaye Fatahi, Sanaz Jamshidi, Marsa Zaroudi
{"title":"作为神经认知和神经精神疾病生物标志物的高级糖化终产物可溶性受体：对照研究荟萃分析","authors":"Ghazaleh Nameni, Shima Jazayeri, Somaye Fatahi, Sanaz Jamshidi, Marsa Zaroudi","doi":"10.1111/eci.14232","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Background & Objectives</h3>\n \n <p>Currently, there is a significant focus on the decrease of soluble receptor of advanced glycation end products (sRAGE) in neurocognitive and neuropsychiatric disorders. sRAGE plays a decoy role against the inflammatory response of advanced glycation end products (AGE), which has led to increased interest in its role in these disorders. This meta-analysis aimed to investigate the significant differences in sRAGE levels between neurocognitive and neuropsychiatric disorders compared to control groups.</p>\n </section>\n \n <section>\n \n <h3> Method</h3>\n \n <p>A systematic review was conducted using the PUBMED, Scopus and Embase databases up to October 2023. Two reviewers assessed agreement for selecting papers based on titles and abstracts, with kappa used to measure agreement and finally publications were scanned according to controlled studies. Effect sizes were calculated as weighted mean differences (WMD) and pooled using a random effects model. Heterogeneity was assessed using I<sup>2</sup>, followed by subgroup analysis and meta-regression tests. Quality assessment was performed using the Newcastle-Ottawa Quality Assessment Scale.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>In total, 16 studies were included in the present meta-analysis. Subjects with neurocognitive (<i>n</i> = 1444) and neuropsychiatric (<i>n</i> = 444) disorders had lower sRAGE levels in case–control (WMD: −0.21, 95% CI: −0.33, −0.10; <i>p</i> <.001) and cross-sectional (WMD: −0.29, 95% CI = −0.44, −0.13, <i>p</i> <.001) studies with high heterogeneity and no publication bias. In subgroup analysis, subjects with cognitive impairment (WMD: −0.87, 95% CI: −1.61, −0.13, <i>p</i> =.000), and age >50 years (WMD: −0.39, 95% CI: −0.74, −0.05, <i>p</i> =.000), had lower sRAGE levels in case–control studies. Also, dementia patients (WMD: −0.41, 95% CI: −0.72, −0.10, <i>p</i> =.014) with age >50 years (WMD: −0.33, 95% CI: −0.54, −0.13, <i>p</i> = 0.000) and in Asian countries (WMD: −0.28, 95% CI: −0.42, −0.13, <i>p</i> =.141) had lower sRAGE levels in cross-sectional studies.</p>\n </section>\n \n <section>\n \n <h3> Conclusion</h3>\n \n <p>This meta-analysis revealed a significant reduction in sRAGE in neurocognitive and neuropsychiatric disorders particularly in Asians and moderate age.</p>\n </section>\n </div>","PeriodicalId":12013,"journal":{"name":"European Journal of Clinical Investigation","volume":null,"pages":null},"PeriodicalIF":4.4000,"publicationDate":"2024-05-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Soluble receptor of advanced glycation end product as a biomarker in neurocognitive and neuropsychiatric disorders: A meta-analysis of controlled studies\",\"authors\":\"Ghazaleh Nameni, Shima Jazayeri, Somaye Fatahi, Sanaz Jamshidi, Marsa Zaroudi\",\"doi\":\"10.1111/eci.14232\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div>\\n \\n \\n <section>\\n \\n <h3> Background & Objectives</h3>\\n \\n <p>Currently, there is a significant focus on the decrease of soluble receptor of advanced glycation end products (sRAGE) in neurocognitive and neuropsychiatric disorders. sRAGE plays a decoy role against the inflammatory response of advanced glycation end products (AGE), which has led to increased interest in its role in these disorders. This meta-analysis aimed to investigate the significant differences in sRAGE levels between neurocognitive and neuropsychiatric disorders compared to control groups.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Method</h3>\\n \\n <p>A systematic review was conducted using the PUBMED, Scopus and Embase databases up to October 2023. Two reviewers assessed agreement for selecting papers based on titles and abstracts, with kappa used to measure agreement and finally publications were scanned according to controlled studies. Effect sizes were calculated as weighted mean differences (WMD) and pooled using a random effects model. Heterogeneity was assessed using I<sup>2</sup>, followed by subgroup analysis and meta-regression tests. Quality assessment was performed using the Newcastle-Ottawa Quality Assessment Scale.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Results</h3>\\n \\n <p>In total, 16 studies were included in the present meta-analysis. Subjects with neurocognitive (<i>n</i> = 1444) and neuropsychiatric (<i>n</i> = 444) disorders had lower sRAGE levels in case–control (WMD: −0.21, 95% CI: −0.33, −0.10; <i>p</i> <.001) and cross-sectional (WMD: −0.29, 95% CI = −0.44, −0.13, <i>p</i> <.001) studies with high heterogeneity and no publication bias. In subgroup analysis, subjects with cognitive impairment (WMD: −0.87, 95% CI: −1.61, −0.13, <i>p</i> =.000), and age >50 years (WMD: −0.39, 95% CI: −0.74, −0.05, <i>p</i> =.000), had lower sRAGE levels in case–control studies. Also, dementia patients (WMD: −0.41, 95% CI: −0.72, −0.10, <i>p</i> =.014) with age >50 years (WMD: −0.33, 95% CI: −0.54, −0.13, <i>p</i> = 0.000) and in Asian countries (WMD: −0.28, 95% CI: −0.42, −0.13, <i>p</i> =.141) had lower sRAGE levels in cross-sectional studies.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Conclusion</h3>\\n \\n <p>This meta-analysis revealed a significant reduction in sRAGE in neurocognitive and neuropsychiatric disorders particularly in Asians and moderate age.</p>\\n </section>\\n </div>\",\"PeriodicalId\":12013,\"journal\":{\"name\":\"European Journal of Clinical Investigation\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":4.4000,\"publicationDate\":\"2024-05-03\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"European Journal of Clinical Investigation\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://onlinelibrary.wiley.com/doi/10.1111/eci.14232\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"MEDICINE, GENERAL & INTERNAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"European Journal of Clinical Investigation","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1111/eci.14232","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}
Soluble receptor of advanced glycation end product as a biomarker in neurocognitive and neuropsychiatric disorders: A meta-analysis of controlled studies
Background & Objectives
Currently, there is a significant focus on the decrease of soluble receptor of advanced glycation end products (sRAGE) in neurocognitive and neuropsychiatric disorders. sRAGE plays a decoy role against the inflammatory response of advanced glycation end products (AGE), which has led to increased interest in its role in these disorders. This meta-analysis aimed to investigate the significant differences in sRAGE levels between neurocognitive and neuropsychiatric disorders compared to control groups.
Method
A systematic review was conducted using the PUBMED, Scopus and Embase databases up to October 2023. Two reviewers assessed agreement for selecting papers based on titles and abstracts, with kappa used to measure agreement and finally publications were scanned according to controlled studies. Effect sizes were calculated as weighted mean differences (WMD) and pooled using a random effects model. Heterogeneity was assessed using I2, followed by subgroup analysis and meta-regression tests. Quality assessment was performed using the Newcastle-Ottawa Quality Assessment Scale.
Results
In total, 16 studies were included in the present meta-analysis. Subjects with neurocognitive (n = 1444) and neuropsychiatric (n = 444) disorders had lower sRAGE levels in case–control (WMD: −0.21, 95% CI: −0.33, −0.10; p <.001) and cross-sectional (WMD: −0.29, 95% CI = −0.44, −0.13, p <.001) studies with high heterogeneity and no publication bias. In subgroup analysis, subjects with cognitive impairment (WMD: −0.87, 95% CI: −1.61, −0.13, p =.000), and age >50 years (WMD: −0.39, 95% CI: −0.74, −0.05, p =.000), had lower sRAGE levels in case–control studies. Also, dementia patients (WMD: −0.41, 95% CI: −0.72, −0.10, p =.014) with age >50 years (WMD: −0.33, 95% CI: −0.54, −0.13, p = 0.000) and in Asian countries (WMD: −0.28, 95% CI: −0.42, −0.13, p =.141) had lower sRAGE levels in cross-sectional studies.
Conclusion
This meta-analysis revealed a significant reduction in sRAGE in neurocognitive and neuropsychiatric disorders particularly in Asians and moderate age.
期刊介绍：
EJCI considers any original contribution from the most sophisticated basic molecular sciences to applied clinical and translational research and evidence-based medicine across a broad range of subspecialties. The EJCI publishes reports of high-quality research that pertain to the genetic, molecular, cellular, or physiological basis of human biology and disease, as well as research that addresses prevalence, diagnosis, course, treatment, and prevention of disease. We are primarily interested in studies directly pertinent to humans, but submission of robust in vitro and animal work is also encouraged. Interdisciplinary work and research using innovative methods and combinations of laboratory, clinical, and epidemiological methodologies and techniques is of great interest to the journal. Several categories of manuscripts (for detailed description see below) are considered: editorials, original articles (also including randomized clinical trials, systematic reviews and meta-analyses), reviews (narrative reviews), opinion articles (including debates, perspectives and commentaries); and letters to the Editor.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
